BMO Capital Markets upgraded shares of Extendicare (TSE:EXE – Free Report) to a hold rating in a report released on Tuesday,Zacks.com reports.
Several other brokerages also recently commented on EXE. Royal Bank of Canada lifted their price target on Extendicare from C$9.50 to C$11.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 28th. TD Securities upped their target price on shares of Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a research note on Thursday, November 14th.
Extendicare Trading Up 0.8 %
Extendicare (TSE:EXE – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported C$0.19 EPS for the quarter. Extendicare had a net margin of 4.28% and a return on equity of 60.00%. During the same period in the prior year, the firm posted $0.13 EPS. Equities analysts predict that Extendicare will post 0.6134729 EPS for the current year.
Extendicare Announces Dividend
The company also recently announced a monthly dividend, which will be paid on Friday, February 14th. Investors of record on Friday, February 14th will be given a $0.04 dividend. The ex-dividend date of this dividend is Friday, January 31st. This represents a $0.48 annualized dividend and a yield of 4.60%. Extendicare’s dividend payout ratio (DPR) is currently 70.59%.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- What Are Treasury Bonds?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- The How and Why of Investing in Gold Stocks
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.